Member Info for equitrder

What shud be the market cap of BOI be? I'm hearing the bankers are having a hard time selling AIB's lofty valuation.

They can go to Australia NZ Hong Kong Singapore Indonesia China.I doubt they will do a deal with the Yanks as they would perceive that there are too many undesirables there. I even know an English born Iranian going back to a very vibrant modern Iran to reclaim his family properties that were confiscated.No Saudi wahhabi terrorists there but of course the Brits and the Yanks are backing the wrong horse again!!!!

Yep Rory Nealon said they would be working on it at the Fastnet meeting in the Doubletree Hilton last April...

Alan Harris, the founder of Som, was involved in developing a therapy for these surgery-resistant patients with Acromegaly when he was at Novartis. The product is called Octreotide, which is now a 1.65 billion dollar product. So, within the cohort of patients who have failed surgical treatment, most of them are on Octreotide or another product called Ianreotide. These are both somatostatin analogues, and will work fully in roughly 30% of patients who try them. The remaining 70% need an alternate treatment. Novartis realised this, as did Pfizer, and developed other products. Novartis brought a product called Pasireotide, and Pfizer brought a product called Pegvisomant. Pegvisomant is a growth hormone receptor antibody. It acts as an antagonist, blocking the receptor and reducing the action of growth hormone. There are two problems with growth hormone receptor antagonists – the first is that it has no effect on the tumour size, only on the action of growth hormone. Secondly, it has a tendency to elevate liver enzymes. Pasireotide, however, is a somatostatin analogue, so it does have an effect on the tumour. It binds to somatostatin receptors two and five. Octreotide only binds to receptor 2. Pasireotide is clinically effective, but it can cause diabetes as a side effect. Alan set up Som Pharmaceuticals to develop a new somatostatin analogue. He wanted to find a product as effective as pasireotide, that did not cause diabetes.

Have you done any DD on AP102? I think Novartis will be looking very closely if its a potential competitor to Pasireotide.I can't get real figures but I think Pasireotide generated over 1.5 bil in revs last year.We are only at the rat stage but they have taken diabetes out of the equation which is significant apparently.

Btw-where's earlybird? I'm surprised he's not taking a shot at me...I'll gladly take shots off people who add to the board. Not like some who grunts like a Neanderthal every now and then....you know who you are... All right SON

In hindsight me thinks management needed time to get all their ducks in a row.I couldn't understand how such a strong management team could let the stock go from .24 to .13 in less than 9 mths. The turning point for me was the EIB which legitimized the company.That was when I increased my holding at .1374 to a nice round figure.At the time I think I said this could be ''a slow burner'. And it was! I was still critical that management were not getting the word out there but recently with acquiring the rights to Lujuxta and the start of Phase 3 Epilsalvan management have the wind behind their sails. Zeiner buying shares in my humble opinion put the stock on people's radar(I wouldn't be surprised if most of the buys the last few days were Germans) Not getting ahead of ourselves we are only back to where we started and we are still an AIM listed stock. Btw I had planned to sell 1/2 at .27 but with the recent news I think our valuation is too low but many will be taking profits soon!

Runoff between far right and far left now on the cards....Undoubtedly a Macron win would cause a huge rally in stock's and the Euro.

Nice post Thinice!!!he doesn't deserve it!!! Radar ur too Goddamn lazy to do due diligence yourself!!!!!! Radar if u remember Richie Boucher bought a small amount of Bank of Ireland it went from .17 to .22 and then to .26.. Pat Plunkett Chairman from Providence Resources bought at .12 and it went to .17.. Jamie Dimon bought a small amount of JPM and turned the market that was in freefall. Now your Filtered!!!

Are ye all DUMB!!!! A member of the Board of Directors just bought 100 k shares

Member of the board just bought 100k shares...

Ticket symbol SOW on the Dax. They owned Birken Pharma(Episalvan)before it merged into Amryt. They spent over 10 mil on Episalvan getting to the merger in 2016

Is one of our largest shareholders at over 20%... Market cap €3 billion and its CFO just bought 100000 shares.. There's alot of employees (4500)in Software AG that might follow the CFO's investments.

Now i know I own .05% of Amryt..

Nice to see insiders buying..for his personal account..

Some shrewd investors bought it up...

Very bullish.. I'm excited about Lujuxta sales and the potential... In time when we become cash flow positive I hope Management start buying up shares and retiring then.Tucows (TCX) did this and the stock has gone from .50 cents to $50 in the last 7 years..my retirement policy(:

Not sure why people are using RBS as an example of a positive reverse split. Stop was trading at £2 now 5 years later its at £2.40. Bank of Ireland has outperformed..

Ahh you can't use those numbers. Most of Ireland's exports are multinationals and aren't real. The 16% to the UK are indigenous industries mostly.It's the heart and soul of Ireland. If the UK does a deal with NZ or Brazil or Aus or Arg for cheap dairy or meat then Irish agri exports are toast.

The Irish stock exchange is a joke..just no liquidity on the smaller companies